News

• West Virginia County Prescription Data Reports & CSMP Data Maps

  4/22/2024
  

  2023 Surveillance Maps

  The WV Violence and Injury Prevention Program (VIPP) received Centers for Disease Control and Prevention (CDC) funding through the Overdose Data to Action (OD2A) cooperative agreement in 2023. An activity under this grant is to improve PDMP infrastructure or information systems to support proactive reporting and data analysis, including enhancing reporting systems to increase frequency and quality of reporting. The VIPP is able to achieve the goal of this activity through collaboration with the West Virginia Board of Pharmacy (BOP), which houses the Controlled Substance Monitoring Program (CSMP). The CDC provided specific indicators to measure opioid prescribing behaviors during the previous cooperative agreement (PDO-PfS) which continue to be used in the state. The BOP and VIPP were interested in modifying these indicators to establish state-specific measures. The results of this analysis were obtained using 2023 CSMP data.

  West Virginia County Prescription Data Reports

  The West Virginia Board of Pharmacy, in collaboration with the West Virginia Violence and Injury Prevention Program (WV VIPP) and the West Virginia University Injury Control Research Center (ICRC), under the direction of the Centers for Disease Control and Prevention (CDC), are working to address prescription drug misuse, diversion, and overdose within the state of West Virginia.  Prescription drug overdose continues to be a major issue in West Virginia.  To help combat this epidemic, CDC provided specific indicators to identify high-risk areas within the state to allow for intervention and community education.  The Executive summary and county specific details for these indicators are available at the following links:

  The link to both can be found below:

  https://dhhr.wv.gov/vip/county-reports/Pages/2023-CSMP-Surveillance-Reports.aspx

• Power Outage

  4/3/2024
  Due to power outage issues the WVBOP office will not be open today, April 3, 2024. The office will not be available by phone. All online submissions, applications and emails will continue to be processed by available staff working from home.We apologize for any inconvenience. We will reopen when the power is back on.

• Drug Diversion Continuing Education Statement:

  3/24/2024
  The 2023 Legislature passed a law that will be implemented this renewal cycle (2024) for pharmacists regarding the Drug Diversion Continuing Education (CE) requirement.

• UPDATED 5-2-23: WVBOP Statement on Semaglutide Compounding

  5/2/2023
  The West Virginia Board of Pharmacy (Board) staff has received inquiries concerning the compounding of semaglutide. This topic has become very prominent across the nation, as the medication has gained notoriety for various reasons. Semaglutide is, of course, a commercially available drug product marketed as Ozempic™ for treating diabetes and as Wegovy™ for weight loss. The Board of Pharmacy in both Mississippi and North Carolina have already issued statements, and the Boards of Pharmacy in other states appear ready to make similar statements.